Isomorphic Labs raises $5 billion for AI drug discovery | Magica
Isomorphic Labs raises $5 billion to push AI drug candidates toward trials
Editorial Team
••📖6 min read
The Alphabet-backed drug developer has announced $7.1 billion in funding in six months. Its new capital will expand proprietary AI models and clinical infrastructure as company-reported preclinical progress awaits testing in patients.
Greenoaks and Sequoia Capital co-led the $5 billion Series C, with continued investment from Alphabet.
The round follows May’s $2.1 billion Series B, bringing the two announced financings to $7.1 billion.
Isomorphic reports positive preclinical results; the funding release does not provide patient outcomes or a date for clinical entry.
Isomorphic Labs, the London-based, Alphabet-backed AI drug developer founded in 2021, announced a $5 billion Series C on November 17 to expand its drug design technology and build the infrastructure needed to advance candidates into clinical trials.
The financing follows another multibillion-dollar round in May, backing a transition from computational drug design toward human testing. Isomorphic reports positive preclinical results in cancer and immune-disease programs, but the new funding announcement supplies neither patient results nor a timetable for its first clinical entry.
Illustration accompanying Isomorphic Labs’ November 17 Series C announcement. Credit: Isomorphic Labs. Source: Isomorphic Labs.
A second multibillion-dollar round in six months
Venture capital firms Greenoaks and Sequoia Capital co-led the round. Andreessen Horowitz and other new investors joined, while Alphabet continued what the company described as significant investment. All existing investors participated: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund, according to the company’s announcement.
New Street Research has initiated Anthropic at Buy ahead of its planned IPO. Its $105 target bets on expanding AI demand, while the filing shows surging revenue and improved customer-serving economics alongside volatile operating results and vast infrastructure commitments.
Editorial Team
In May, Isomorphic already said proceeds would develop and deploy its drug design engine, expand therapeutic programs toward the clinic and support hiring across AI, engineering, drug design and clinical work. November’s round adds capital behind that same transition. The latest release does not disclose a valuation, individual investment amounts or resulting ownership stakes, so it does not establish how the financing changes control.
Company-reported funding round sizes in 2026. These amounts describe announced financing, not spending or valuation. Chart: Magica; source: Isomorphic Labs. Source: Isomorphic Labs Series B announcement.
From protein prediction to a drug pipeline
Founder and chief executive Demis Hassabis also co-founded DeepMind, the Alphabet AI research organization whose protein-prediction work provided Isomorphic’s starting point. Isomorphic launched from DeepMind in 2021 as an Alphabet subsidiary to build on AlphaFold, according to its 2022 management announcement, which identified Hassabis as CEO of both organizations. AlphaFold is software that predicts protein structures.
That history explains the scientific starting point, but Isomorphic’s current proposition reaches beyond predicting a protein’s shape. The company describes its proprietary Isomorphic Labs Drug Design Engine, or IsoDDE, as a system combining simulation models across therapeutic areas and types of medicine. It says those models, working with proprietary AI agents that reason about biological systems, help its researchers design and refine molecules with suitable drug properties.
IsoDDE also predates this financing. In a February 2026 technology update, Isomorphic described it as a unified computational drug-design system extending beyond AlphaFold 3, the model it released with Google DeepMind in 2024. The update acknowledged a limitation of the earlier approach: understanding biomolecular structures alone was insufficient to conduct real-world drug discovery on a computer.
The company supplied narrower performance claims to support its case. It said IsoDDE more than doubled AlphaFold 3’s protein–ligand structure-prediction accuracy on the hardest category of the Runs N’ Poses benchmark: systems in the 0–20 similarity bin, the most dissimilar to training examples. That comparison tests prediction on unfamiliar protein–molecule combinations; it does not measure the rate at which drug candidates succeed in patients. Isomorphic also reported identifying previously uncharacterized binding pockets—sites where a molecule could attach—from a protein’s amino acid sequence, without requiring a known binding molecule as input.
The update also compared IsoDDE with AlphaFold 3 and the Boltz-2 model on antibody–antigen structure prediction, and with physics-based methods on binding affinity—how strongly a molecule binds to its target. Isomorphic claimed faster, cheaper binding-affinity predictions than physics-based approaches. These are company evaluations of particular computational tasks, rather than evidence of lower total drug-development costs. The November funding release gives no computing-capacity requirement or cost breakdown with which to assess the economics of scaling the engine.
In the funding release, Isomorphic reports positive preclinical results in internal oncology and immunology programs and in partnered work. It plans to improve IsoDDE, develop models for additional biology and build partnerships to understand disease mechanisms. The release supplies no numerical preclinical results with which to assess those programs.
Company-reported protein–ligand prediction success on the hardest Runs N’ Poses category, with similarity to training examples in the (0–20] bin. This benchmark does not measure patient outcomes. Credit: Isomorphic Labs. Source: Isomorphic Labs drug design engine update.
Partnerships show a commercial route, with conditions
Isomorphic develops both wholly owned programs and programs with partners. That gives its technology two routes toward medicines: candidates retained internally and discovery work conducted with pharmaceutical companies. Its May funding announcement named Johnson & Johnson alongside Lilly and Novartis as strategic partners, although it did not provide terms for the Johnson & Johnson collaboration.
Its January 2024 collaboration announcement provides an earlier measure of commercial interest. Agreements with Eli Lilly and Novartis covered multiple targets and small-molecule discovery. Isomorphic said they could be worth nearly $3 billion excluding royalties, combining upfront and milestone payments. The stated upfront amounts were $45 million from Lilly and $37.5 million from Novartis—a combined $82.5 million.
The distinction matters: potential milestone revenue is conditional, whereas the upfront amounts describe the initial contractual payments. The headline partnership value therefore cannot be treated as money already received or as evidence that the resulting drugs work. Nor does it measure the same thing as an equity financing round.
The next test is clinical evidence
Isomorphic says the new proceeds will also build global infrastructure, including capabilities for translational work and clinical development, as its candidates advance toward trials. In a report on the financing, Hassabis likewise said the lab planned to use the capital to accelerate its move toward clinical trials.
The funding announcement does not specify which candidate will enter trials first, the timing of that entry or a budget split between models and drug development. Its descriptions of positive preclinical work establish the stage of the reported progress, rather than patient benefit.
The next evidence needed is which programs reach human testing, what those trials are designed to establish and what results they produce. That will test a different proposition from the computational benchmarks: whether the molecules designed with Isomorphic’s engine can become effective medicines for patients.
Microsoft enters Ignite with a previously announced Copilot redesign that combines office applications and autonomous agents. Availability, usage-based charges and reliability will determine what that expansion means for customers, while October's missing paid-seat update leaves adoption harder to assess.
A proposed Equity–Pact agreement would give UK film and TV performers consent and payment rights over digital replicas. Members must approve the package, which leaves explicit protections against AI training unresolved.
The French cloud provider plans to release Olala mini 7A1B on November 19, backed by acquired expertise and European public computing support. Its first deployment offers cost claims, but no published benchmarks yet establish its competitive quality.
US stock futures fell before Nvidia's first earnings report since Jensen Huang's departure, with cash generation, tighter export controls and rate-hike expectations clouding the AI trade ahead of Anthropic's expected market debut.
Nvidia has created a standing board committee to oversee national security and export compliance after co-founder Jensen Huang’s departure. Investigation findings and operational changes remain unresolved.
Microsoft's CEO says team sizes, workflows and skills will change as AI reshapes engineering. About 60,000 employees are eligible for voluntary exits, but uptake and the prospect of later layoffs remain unresolved.
Hong Kong officials say financial firms and their human overseers remain responsible for AI agents. With 36 projects selected for sandbox testing, the unresolved task is turning that principle into reliable identity checks, delegated authority and human intervention.
Meta says stronger AI checks and India-specific tuning keep more suggestive and violent content out of Instagram recommendations. Its reporting metric leaves exposure unmeasured, while a government request to change ranking systems drew objections over the ministry’s authority.
OpenAI says NATO has used up to 300 billion raw input and output tokens a month for cyber defence. Access through NATO’s technology agency and an AI-agent exercise shows uptake, while costs, comparative performance and NATO-specific security results remain undisclosed.
Numa’s Series C finances a move from customer conversations into sales and service operations. Automaker distribution gives it reach, but vendor approvals and company-reported savings leave the broader operating-system pitch to prove.
Google’s research tool can turn uploaded sources into interactive dashboards, study aids and trackers. Shared links require full notebook access, personal inputs stay separate, and generation draws on compute-based usage limits.
Records detail Chinese data-center investments linked to Hexi founder Kang Wei, husband of former Megaspeed chief Alice Huang. Filings document financing and Huawei business, but do not establish a route for restricted Nvidia chips.
ElevenLabs plans to acquire Kotoba, the startup behind Japanese speech technology used in Salesforce’s Agentforce Voice. The deal adds a 15-person team and deployed products to its existing Japanese operation, but financial terms and integration plans remain undisclosed.
Tesla plans €3 billion of expansion at its profitable Grünheide factory to build Cybercabs from 2029, eventually targeting up to one million annually. The driverless taxi still lacks German and EU approval, and its capacity target differs from an older plan for the whole site.
Our World in Data’s comparison finds negative views of AI exceed positive ones across five probability-based surveys. The primary results also reveal substantial mixed views, acceptance of some applications and a sharper divide over who controls development and bears its local costs.
NVIDIA's Nemotron for Science pairs an existing open model with nearly 50,000 chemistry questions and scientific post-training recipes. Partner results suggest scope for specialized agents, but the reported accuracy and inference savings do not establish the full cost of adapting them.
AMD says the Lux AI supercomputer is open to scientific users at Oak Ridge. Half its annual capacity supports the Genesis Mission and half is reserved for paid access, including AMD development, while workload limits and undisclosed rates shape its practical value.
Apple is adding app-by-app and folder-specific permissions, repeat approval requests and clearer warnings in macOS 27.3 beta 2. Existing permissions remain intact, limiting the immediate reach of the privacy changes.
OpenAI reportedly discussed buying Goodfire for more than $5 billion, over four times its February financing valuation. No deal resulted. A disclosed paid assessment agreement offers cooperation without ownership, while the technology’s safety benefits remain to be demonstrated.